Taysha Gene Therapies reported a Q2 2025 net loss of $26.9M, driven by increased R&D and legal expenses tied to the REVEAL trial and regulatory preparations. Revenue was $2.0M, while cash reserves rose to $312.8M after a $230M follow-on offering.

The company narrowed its net loss year-over-year and made notable regulatory strides for its TSHA-102 Rett syndrome program, receiving FDA alignment on the pivotal trial design.

Taysha Gene Therapies reported a net loss of $89.3 million for the full year ended December 31, 2024, an improvement from the $111.6 million net loss in the prior year. The company's TSHA-102 clinical program for Rett syndrome showed continued progress, with high and low doses being generally well tolerated across all treated patients. Research and development expenses increased to $66.0 million, driven by manufacturing and clinical trial activities, while general and administrative expenses decreased slightly.

Taysha Gene Therapies reported its Q3 2024 financial results, highlighting progress with the FDA on the regulatory pathway for TSHA-102 and FDA approval to use the pivotal product in REVEAL trials. The company's cash resources are expected to support operations into the fourth quarter of 2026.

Taysha Gene Therapies reported a net loss of $20.9 million for the second quarter of 2024. The company's cash and cash equivalents totaled $172.7 million as of June 30, 2024, which is expected to support operations into the fourth quarter of 2026.

Taysha Gene Therapies reported a net loss of $24.1 million, or $0.10 per share, for the first quarter ended March 31, 2024. As of March 31, 2024, Taysha had $124.0 million in cash and cash equivalents, which is expected to support planned operating expenses and capital requirements into 2026. The company is advancing its TSHA-102 program in clinical evaluation for Rett syndrome and received RMAT designation for TSHA-102 from the FDA.

Taysha Gene Therapies reported full-year 2023 financial results, with revenue of $15.5 million compared to $2.5 million in 2022. The company's net loss was $111.6 million, or $0.96 per share, compared to a net loss of $166.0 million, or $3.78 per share in 2022. As of December 31, 2023, Taysha had $143.9 million in cash and cash equivalents.

Taysha Gene Therapies reported a net loss of $117.1 million for the third quarter of 2023, driven by a non-cash expense related to a change in the fair value of warrant liability. The company's cash and cash equivalents totaled $164.3 million as of September 30, 2023, expected to fund operations into 2026.

Taysha Gene Therapies reported financial results for Q2 2023, with a net loss of $24.6 million, or $0.38 per share. The company's cash and cash equivalents totaled $45.1 million as of June 30, 2023. A private placement financing is expected to result in gross proceeds of approximately $150 million, extending the cash runway into the third quarter of 2025.

Taysha Gene Therapies reported a net loss of $17.6 million for the first quarter of 2023, which was partially offset by revenue of $4.7 million from Astellas Transactions. The company's cash and cash equivalents were $63.4 million as of March 31, 2023, which is expected to support planned operations into the first quarter of 2024.

Taysha Gene Therapies reported its Q4 and full-year 2022 financial results. They initiated screening for their REVEAL Rett syndrome trial and are on track for first patient dosing in H1 2023. A protocol amendment was submitted to allow younger patients in the study. FDA feedback suggests alternative trial designs for TSHA-120 in GAN.

Taysha Gene Therapies reported a net loss of $26.3 million for the third quarter of 2022. They secured a $50 million strategic investment from Astellas Pharma and proceeds from a follow-on offering, extending their cash runway into the first quarter of 2024.

Taysha Gene Therapies reported progress in giant axonal neuropathy (GAN) with TSHA-120, demonstrating durable neurophysiological improvements. Positive feedback from MHRA supports regulatory strategy and manufacturing approach. Preclinical data for TSHA-102 in Rett syndrome showed near normalization of survival and behavior in neonatal knockout Rett mice.

Taysha Gene Therapies reported a net loss of $50.1 million for the first quarter of 2022. Research and development expenses were $37.8 million, and general and administrative expenses were $11.5 million. As of March 31, 2022, the company had $96.6 million in cash and cash equivalents.

Taysha Gene Therapies reported a net loss of $50.4 million for the fourth quarter of 2021. The company is prioritizing key registration-directed programs in GAN and Rett syndrome and expects its cash runway to extend into Q4 2023.

Taysha Gene Therapies reported a net loss of $51.2 million for Q3 2021. The company made significant advances across multiple programs, including regulatory meetings and preclinical data publications.

Taysha Gene Therapies reported a net loss of $40.9 million for the second quarter ended June 30, 2021. The company had $197.4 million in cash and cash equivalents as of June 30, 2021. They also secured a non-dilutive term loan for up to $100 million.

Taysha Gene Therapies reported a net loss of $32.0 million, or $0.87 per share, for the first quarter ended March 31, 2021. As of March 31, 2021, Taysha had $228.7 million in cash and cash equivalents.

Taysha Gene Therapies reported its full-year 2020 financial results, highlighting significant progress in its pipeline initiatives, technology platforms, and manufacturing strategy. The company anticipates a transformational year in 2021 with upcoming clinical data and trial initiations.